Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Crystal structure of human cathepsin K complexed with a potent inhibitor.

McGrath ME, Klaus JL, Barnes MG, Brömme D.

Nat Struct Biol. 1997 Feb;4(2):105-9. No abstract available.

PMID:
9033587
2.

Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.

Marquis RW, Yamashita DS, Ru Y, LoCastro SM, Oh HJ, Erhard KF, DesJarlais RL, Head MS, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, Tomaszek TA, Levy MA, Veber DF.

J Med Chem. 1998 Sep 10;41(19):3563-7. No abstract available.

PMID:
9733481
3.

Crystal structure of human cathepsin V.

Somoza JR, Zhan H, Bowman KK, Yu L, Mortara KD, Palmer JT, Clark JM, McGrath ME.

Biochemistry. 2000 Oct 17;39(41):12543-51. Erratum in: Biochemistry 2001 Apr 3;40(13):4200.

PMID:
11027133
4.

Crystal structure of human osteoclast cathepsin K complex with E-64.

Zhao B, Janson CA, Amegadzie BY, D'Alessio K, Griffin C, Hanning CR, Jones C, Kurdyla J, McQueney M, Qiu X, Smith WW, Abdel-Meguid SS.

Nat Struct Biol. 1997 Feb;4(2):109-11. No abstract available.

PMID:
9033588
5.

Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.

Thompson SK, Smith WW, Zhao B, Halbert SM, Tomaszek TA, Tew DG, Levy MA, Janson CA, DAlessio KJ, McQueney MS, Kurdyla J, Jones CS, DesJarlais RL, Abdel-Meguid SS, Veber DF.

J Med Chem. 1998 Oct 8;41(21):3923-7.

PMID:
9767629
6.

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1735-9. Epub 2006 Jan 11.

PMID:
16376075
7.

Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.

Altmann E, Cowan-Jacob SW, Missbach M.

J Med Chem. 2004 Nov 18;47(24):5833-6.

PMID:
15537340
8.

Human cathepsin X. A novel cysteine protease with unique specificity.

Ménard R, Nägler DK, Zhang R, Tam W, Sulea T, Purisima EO.

Adv Exp Med Biol. 2000;477:317-22. No abstract available.

PMID:
10849759
9.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Alper PB, Liu H, Chatterjee AK, Nguyen KT, Tully DC, Tumanut C, Li J, Harris JL, Tuntland T, Chang J, Gordon P, Hollenbeck T, Karanewsky DS.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1486-90. Epub 2006 Jan 18.

PMID:
16412634
10.

Identification of a potent and selective non-basic cathepsin K inhibitor.

Li CS, Deschenes D, Desmarais S, Falgueyret JP, Gauthier JY, Kimmel DB, Léger S, Massé F, McGrath ME, McKay DJ, Percival MD, Riendeau D, Rodan SB, Thérien M, Truong VL, Wesolowski G, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1985-9. Epub 2006 Jan 18.

PMID:
16413777
11.

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.

Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):22-7. Epub 2006 Nov 17.

PMID:
17157021
12.

Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.

LaLonde JM, Zhao B, Smith WW, Janson CA, DesJarlais RL, Tomaszek TA, Carr TJ, Thompson SK, Oh HJ, Yamashita DS, Veber DF, Abdel-Meguid SS.

J Med Chem. 1998 Nov 5;41(23):4567-76.

PMID:
9804696
13.

The SEP domain of p47 acts as a reversible competitive inhibitor of cathepsin L.

Soukenik M, Diehl A, Leidert M, Sievert V, Büssow K, Leitner D, Labudde D, Ball LJ, Lechner A, Nägler DK, Oschkinat H.

FEBS Lett. 2004 Oct 22;576(3):358-62.

14.

Acyclic cyanamide-based inhibitors of cathepsin K.

Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.

PMID:
15896958
15.

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M.

Bone. 2002 May;30(5):746-53.

PMID:
11996914
16.

Exploring inhibitor binding at the S' subsites of cathepsin L.

Chowdhury SF, Joseph L, Kumar S, Tulsidas SR, Bhat S, Ziomek E, Ménard R, Sivaraman J, Purisima EO.

J Med Chem. 2008 Mar 13;51(5):1361-8. doi: 10.1021/jm701190v. Epub 2008 Feb 16.

PMID:
18278855
17.

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ.

J Med Chem. 2004 Jan 29;47(3):588-99.

PMID:
14736240
18.

Azepanone-based inhibitors of human cathepsin L.

Marquis RW, James I, Zeng J, Trout RE, Thompson S, Rahman A, Yamashita DS, Xie R, Ru Y, Gress CJ, Blake S, Lark MA, Hwang SM, Tomaszek T, Offen P, Head MS, Cummings MD, Veber DF.

J Med Chem. 2005 Nov 3;48(22):6870-8.

PMID:
16250645
19.

Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K.

Duffy KJ, Ridgers LH, DesJarlais RL, Tomaszek TA, Bossard MJ, Thompson SK, Keenan RM, Veber DF.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1907-10.

PMID:
10450951
20.

Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.

Altmann E, Green J, Tintelnot-Blomley M.

Bioorg Med Chem Lett. 2003 Jun 16;13(12):1997-2001.

PMID:
12781182
Items per page

Supplemental Content

Write to the Help Desk